Lisa J Wood, Ph.D., R.N.
- click here
Summary of Current Research
The long-range goal of our research is to effectively treat and manage the most common symptom experienced by cancer patients undergoing chemotherapy, radiation therapy or both; fatigue. To date the molecular mechanisms underlying the initiation and perpetuation of CTRF are not well established, and, the precise role of inflammatory cytokines, if any, in CTRF remains unclear. Our research program utilizes a pre-clinical and clinical approach to examine the relationship between cancer treatment, inflammatory cytokines and CTRF. This “bench to bedside” approach to understanding the cause of CTRF arises from a unique interdisciplinary collaboration among molecular, behavioral, and clinical investigators all working at various points within the spectrum of cancer research at our institution and hence, represents a major innovation in cancer symptom research.
"A role for orexin in cytotoxic chemotherapy-induced fatigue,"
"Preliminary differences in peripheral immune markers and brain metabolites between fatigued and non-fatigued breast cancer survivors: a pilot study,"
"Preliminary evidence of a blunted anti-inflammatory response to exhaustive exercise in fibromyalgia,"
"Production of IL-1Î² by bone marrow-derived macrophages in response to chemotherapeutic drugs: Synergistic effects of doxorubicin and vincristine,"
"The role of IL-1Î² and TNF-Î± signaling in the genesis of cancer treatment related symptoms (CTRS): A study using cytokine receptor-deficient mice,"